Valvular heart disease associated with benfluorex therapy: Results from the French multicentre registry
| Autor: | J. Rousseau, Jean-Christophe Eicher, Gilbert Habib, Sylvestre Maréchaux, Christophe Tribouilloy, B. Blanchard-Lemoine, Yves Etienne, Yannick Jobic, Pierre Henon, F. le Ven, Jean-Pierre Gueffet |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty Hypertension Pulmonary Heart Valve Diseases Comorbidity Body Mass Index chemistry.chemical_compound Risk Factors Internal medicine Mitral valve Appetite Depressants Fenfluramine medicine Humans Radiology Nuclear Medicine and imaging Obesity Registries Retrospective Studies Benfluorex Dose-Response Relationship Drug Cumulative dose business.industry valvular heart disease Retrospective cohort study General Medicine Middle Aged medicine.disease Surgery Treatment Outcome medicine.anatomical_structure chemistry Heart failure cardiovascular system Cardiology Female France business Cardiology and Cardiovascular Medicine Body mass index Echocardiography Transesophageal |
| Zdroj: | Archives of Cardiovascular Diseases. 104(4):292-293 |
| ISSN: | 1875-2136 |
| DOI: | 10.1016/j.acvd.2011.03.071 |
| Popis: | Aims The aim of this paper is to report clinical characteristics, consequences, echocardiographic features, and pathological findings encountered in patients suffering from valvular disease associated with benfluorex exposure in a multicentre French registry. Methods and results Forty patients suffering from unexplained restrictive valvular disease with a previous exposition to benfluorex, a fenfluramine derivative, were identified from eight French university hospitals. Patients were mostly women (87.5%) with a mean age of 57 ± 9 years and high body mass index of 30 ± 7 kg/m²; 37.5% of them presented with severe heart failure symptoms (NYHA class III and IV). Benfluorex mean daily dose was 415 ± 131 mg with total therapy duration of 72 ± 53 months. Resulting cumulative dose was 910 ± 675 g. Common echocardiographic findings were leaflets and sub-valvular apparatus thickening and retraction. Aortic and mitral valve regurgitations resulting from leaflets loss of coaptation were the most frequent findings (87.5 and 82.5%) and were severe in 29 patients (72.5%). Multiple valve involvements were present in 31 cases (77.5%). Pulmonary arterial hypertension was identified in 20 cases (50%). Histopathological examination demonstrated abundant extra cellular matrix encasing the leaflets without modification of valve architecture. Fifteen patients (37.5%) underwent valvular surgery. Conclusion Benfluorex-related valvulopathy shares numerous characteristics with other drug-induced valvular disease. Clinical consequences may be serious with severe heart failure symptoms that may lead to surgical treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect